<div id="readability-page-1"><p>Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $157.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Burnett is an analyst with an average return of <span>-3.0%</span> and a 40.50% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, Xenon, and MannKind.</p> <p>In addition to Wells Fargo, Axsome Therapeutics also received a Buy from RBC Capital’s Leonid Timashev in a report issued on December 12. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).</p></div>

AXSM

<p>Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Axsome Therapeutics with a price target of $157. RBC Capital also issued a Buy rating, while TR reiterated a Hold rating. Burnett, covering the Healthcare sector, has an average return of -3.0% and a 40.50% success rate.</p>

Axsome Therapeutics (AXSM) Receives a Buy from Wells Fargo